Network Collaborators Announced for CADTH’s Post-Market Drug Evaluation Network

CADTH is pleased to announce the successful collaborators of its inaugural Post-Market Drug Evaluation (PMDE) Network. Collaborators will bring additional expertise to the PMDE Network and will respond to decision-makers’ queries by providing expertise and evidence in the post-market space.

The PMDE Program issued a request for proposals on March 15, 2022, for its Contractors. Proposals were reviewed by a multidisciplinary review panel that identified the following applicants to be PMDE Network Collaborators:

  • The Canadian Network for Advanced Interdisciplinary Methods for comparative effectiveness research (CAN-AIM), led by Dr. Sasha Bernatsky and hosted by the Research Institute of the McGill University Health Centre.
  • Exactis – Personalize my Treatment (PMT) Network Cancer Patient Registry, led by Dr. Kostas Trakas and hosted by Exactis Innovation.
  • ActionADE (Adverse Drug Events), led by Dr. Corinne Hohl and hosted by the University of British Columbia.
  • Drs. Fiona Clement, Mina Tadrous, and Michael Law.
  • Active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare and Pharmacogenomics of Adverse Reaction Events National Team (SEARCH & PREVENT), led by Drs. Bruce Carleton and Colin Ross and hosted by the University of British Columbia.

These collaborators bring decades of experience in the post-market landscape and are well prepared to respond to the needs of federal, provincial, and territorial decision-makers.

The PMDE Program will launch September 1, 2022, and contracts will be issued to these individuals or teams as queries are received by the PMDE Program.

If you have any questions about the PMDE Program or Network, please contact [email protected].